- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03408340
Paravertebral Nerve Blocks in Neonates
Paravertebral Nerve Blocks in Neonates and Infants Undergoing Repair of Aortic Coarctation, A Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pain and pain control remain a major concern in the neonatal and infant populations and pain is often undertreated in order to achieve other goals of medical management. Pain control with narcotic medications create an additional concern as withdrawal from narcotics can become an issue in neonates and infants requiring long-term administration of pain medications. A regional block is an alternative way to control pain by directly blocking the nerves through injecting medication near their course.
A paravertebral block (PVB) is a regional block of some of the spinal nerves. The paravertebral space is a wedge shaped space that is located next to the bony structures of the spine. This space is where the nerves of the spine branch out to the body which makes this space an ideal location to deliver numbing drugs for pain. An ultrasound probe is used to ensure that the medicine goes into the paravertebral space. This study will compare the use of the standard of care intravenous pain medication to the use of a PVB.
Using a PVB to control pain may also lead to better blood flow to the spinal cord. A Near Infrared Spectroscopy (NIRS) monitor will be used to monitor the oxygen levels in the spine tissues. This study aims to determine if using a paravertebral block in addition to standard of care anesthesia results in better pain control and blood flow to the spine.
A total of 30 neonates and infants, defined as children less than 12 months of age, will be enrolled in this study. The subjects will be scheduled for elective or semi-elective cardiac surgery at Children's Healthcare of Atlanta. At the time of surgery they must be greater than or equal to 2.5 kg and undergoing aortic coarctation repair via left thoracotomy.
Post-operative pain control in either the control or experimental (paravertebral nerve block) group will be accomplished with intravenous, rectal, and oral analgesics. Patients will receive scheduled rectal acetaminophen while intubated and oral acetaminophen once they have progressed to oral intake of formula. Intravenous fentanyl will be used for breakthrough pain while intubated and until oral intake is tolerated. Once oral intake is resumed, the patient will be provided with oral oxycodone as needed for pain per usual Cardiac Intensive Care Unit (CICU) care. If the patient is not yet ready for extubation and requires additional sedation, intravenous doses of midazolam may be required.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Justin B Long, MD
- Phone Number: 404-785-6670
- Email: justin.bradley.long@emory.edu
Study Contact Backup
- Name: Kati Miller
- Phone Number: 404-729-0492
- Email: Kati.Miller@choa.org
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Recruiting
- Children's Healtcare of Atlanta
-
Contact:
- Justin B Long, MD
- Phone Number: 404-785-6670
- Email: justin.bradley.long@emory.edu
-
Contact:
- Kati Miller
- Phone Number: 404-729-0492
- Email: Kati.Miller@choa.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Neonate or Infant (<12 months age) at the time of surgery
- Weigh of 2.5 kilograms or more at the time of surgery
- Undergoing aortic coarctation repair via left thoracotomy
- Parent or legal guardian willing to participate, and able to understand and sign the provided informed consent
Exclusion Criteria:
- Intubated prior to surgery (patients who have been intubated and subsequently extubated may be included)
- Ongoing septicemia or localized skin infection on the back
- Parent or legal guardian unwilling to participate or unable to understand and sign the provided informed consent
- Known coagulation defect
- Allergy to local anesthetics
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paravertebral Nerve Block
Participants in the experimental arm will undergo an anesthetic that includes the regional anesthetic technique, paravertebral nerve block.
|
Participants will be induced for anesthesia with propofol 3 milligram/kilogram (mg/kg) or ketamine 2mg/kg (if there is intravenous (IV) access) or sevoflurane with 1 microgram/kilogram (mcg/kg) of fentanyl and 1.2 mg/kg rocuronium once IV access is established.
A NIRS pad will be used for cerebral oximetry as well as another NIRS pad for spinal cord oximetry.
The patient will be intubated, and then will be positioned laterally for the nerve block at approximately the left T3-4 level.
A linear ultrasound probe with a sterile sheath will be used to provide imaging for the paravertebral nerve block.
The injected solution will be 1 milliliter/kilogram (mL/kg) of 0.2% ropivacaine with 5 mcg/mL (1:200,000) epinephrine.
Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane.
The skin will not be infiltrated with additional local anesthetic at the conclusion of the case.
Other Names:
|
Active Comparator: Standard of Care Anesthesia
Participants in the control arm will undergo an anesthetic consistent with the standard of care.
|
Participants in this arm will be induced for anesthesia with propofol 3mg/kg or ketamine 2mg/kg (if there is intravenous access) or sevoflurane with 1 mcg/kg of fentanyl and 1.2 mg/kg rocuronium once IV access is established.
The patient will be intubated; intravenous and intra-arterial access will be obtained and the patient will be positioned for surgery.
Fentanyl may be used as needed for additional analgesia and anesthesia will be maintained with sevoflurane.
The skin will be infiltrated at the conclusion of surgery with less than 1 mL/kg of 0.25% bupivacaine with epinephrine 1:200,000.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Morphine equivalents
Time Frame: 48 hours after surgery
|
To measure total narcotic administration, all narcotics used in the 48-hour postoperative period will be tabulated and converted to morphine equivalents.
The total morphine equivalents will be compared between study arms.
|
48 hours after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Near infrared spectroscopy (NIRS) values
Time Frame: At the end of surgery
|
Spinal cord perfusion will be assessed by continuous measurement of spinal cord near infrared spectroscopy (NIRS) values during repair of aortic coarctation, including the aortic cross clamp period.
(NIRS), a non-invasive light probe that measures regional oxygen saturation.
Decreased spinal cord perfusion (compromised blood flow) is associated with severe morbidities.
|
At the end of surgery
|
Postoperative ventilation time
Time Frame: Up to 2 days (typical duration of time in ICU post-surgery)
|
Postoperative ventilation time will be measured as the time, in minutes, until extubation.
This time will be compared between study arms.
|
Up to 2 days (typical duration of time in ICU post-surgery)
|
Time to first feeding
Time Frame: Up to 7 days (typical duration of time until hospital discharge)
|
Return to feeding after surgery will be measured as hours until the first postoperative feeding.
|
Up to 7 days (typical duration of time until hospital discharge)
|
Change in plasma epinephrine levels
Time Frame: Baseline, 24 hours after surgery
|
Stress response to surgery will be evaluated by measuring plasma epinephrine levels at baseline (before incision), postoperatively (just before transfer to the Intensive Care Unit), and 24 hours postoperatively.
|
Baseline, 24 hours after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Justin B Long, MD, Emory University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Congenital Abnormalities
- Cardiovascular Abnormalities
- Heart Diseases
- Heart Defects, Congenital
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anesthetics, Dissociative
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Excitatory Amino Acid Antagonists
- Excitatory Amino Acid Agents
- Platelet Aggregation Inhibitors
- Analgesics, Opioid
- Narcotics
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anesthetics, Inhalation
- Neuromuscular Agents
- Neuromuscular Nondepolarizing Agents
- Neuromuscular Blocking Agents
- Ketamine
- Fentanyl
- Propofol
- Sevoflurane
- Rocuronium
Other Study ID Numbers
- IRB00093442
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Congenital Heart Disease
-
University of UlsterBelfast Health and Social Care TrustCompletedCongenital Heart Disease | Congenital Heart Defect | Adult Congenital Heart DiseaseUnited Kingdom
-
Children's Hospital Medical Center, CincinnatiNational Heart, Lung, and Blood Institute (NHLBI)CompletedHeart Disease CongenitalUnited States
-
Vanderbilt University Medical CenterEnrolling by invitationCongenital Heart Disease | Congenital Heart Defect | Congenital Heart MalformationsUnited States
-
YHAlattarNot yet recruitingCritical Congenital Heart Disease
-
University Hospital TuebingenCompletedComplex Congenital Heart DiseaseGermany
-
The Hospital for Sick ChildrenCompletedCongenital Heart Disease (CHD)Canada
-
University College, LondonSociety for Cardiothoracic Surgery in Great Britain & Ireland; British Congenital...Unknown
-
University of California, DavisCompletedCyanotic Congenital Heart DiseaseUnited States
-
Assistance Publique Hopitaux De MarseilleRecruitingComplex Congenital Heart DiseaseFrance
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI); Boston Children's HospitalEnrolling by invitation
Clinical Trials on Paravertebral Nerve Block
-
University of PittsburghCompletedTotal Hip ArthroplastyUnited States
-
Charles LukeCompletedThoracic Surgical ProceduresUnited States
-
Jianghui XuCompleted
-
Spectrum Health HospitalsTerminated
-
University of North Carolina, Chapel HillCompletedRegional Anesthesia SuccessUnited States
-
Larissa University HospitalUnknownBreast Surgery | Autonomic Nervous System | Thoracic Paravertebral Block | HRVGreece
-
Lawson Health Research InstituteSt. Joseph's Health Care LondonCompleted
-
Memorial Medical CenterU.S. Army Medical Research and Development Command; Henry M. Jackson Foundation...Terminated
-
Makassed General HospitalRecruiting